Cargando…

The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD

INTRODUCTION: To evaluate and compare the efficacy and safety of YAG laser vitreolysis in treating symptomatic vitreous floaters of complete posterior vitreous detachment (PVD) and non-PVD. METHODS: In this prospective cohort study, 51 eyes with symptomatic floaters were treated with YAG laser vitre...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Tiezhu, Li, Tongtong, Zhang, Xinmei, Hui, Yannian, Moutari, Salissou, Pazo, Emmanuel Eric, Dai, Guangzheng, Shen, Lijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770727/
https://www.ncbi.nlm.nih.gov/pubmed/34778916
http://dx.doi.org/10.1007/s40123-021-00422-6
_version_ 1784635429494980608
author Lin, Tiezhu
Li, Tongtong
Zhang, Xinmei
Hui, Yannian
Moutari, Salissou
Pazo, Emmanuel Eric
Dai, Guangzheng
Shen, Lijun
author_facet Lin, Tiezhu
Li, Tongtong
Zhang, Xinmei
Hui, Yannian
Moutari, Salissou
Pazo, Emmanuel Eric
Dai, Guangzheng
Shen, Lijun
author_sort Lin, Tiezhu
collection PubMed
description INTRODUCTION: To evaluate and compare the efficacy and safety of YAG laser vitreolysis in treating symptomatic vitreous floaters of complete posterior vitreous detachment (PVD) and non-PVD. METHODS: In this prospective cohort study, 51 eyes with symptomatic floaters were treated with YAG laser vitreolysis. Participants were divided into complete PVD and non-PVD groups. Objective visual quality measures including the Strehl ratio (SR), internal spherical aberration (SA), internal comatic aberration (CA), internal high-order aberration (HOA), area ratio of modulation transfer function (MTFa) and Vitreous Floaters Symptom Questionnaire (VFSQ-13) scores were used to compare the efficacy of YAG laser vitreolysis treatment between two groups. RESULTS: The mean age of all patients was 56.80 ± 10.82 years old. In total, 36 of 51 (70.59%; 95% CI 58.10–83.10) patients reported their symptoms as significant or complete improvement after YAG laser vitreolysis treatment. Post-treatment MTFa, internal SA and internal HOA were significantly better compared to baseline (26.19 ± 14.73 vs. 29.19 ± 17.98, p = 0.013; 0.05 ± 0.05 vs. 0.04 ± 0.04, p = 0.031 and 0.23 ± 0.22 vs. 0.16 ± 0.07, p = 0.044; respectively) in all eyes. Twenty-nine of 51 (56.86%) eyes had floaters of non-PVD type. Significant or complete subjective improvements in the PVD group and non-PVD group were 72.73% and 68.97% (p = 0.344), respectively. CONCLUSIONS: Improved subjective and objective visual quality in participants with symptomatic floaters following YAG laser vitreolysis was found in both groups. The efficacy of YAG laser vitreolysis was comparable in floaters of complete PVD and non-PVD types. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-021-00422-6.
format Online
Article
Text
id pubmed-8770727
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-87707272022-02-02 The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD Lin, Tiezhu Li, Tongtong Zhang, Xinmei Hui, Yannian Moutari, Salissou Pazo, Emmanuel Eric Dai, Guangzheng Shen, Lijun Ophthalmol Ther Original Research INTRODUCTION: To evaluate and compare the efficacy and safety of YAG laser vitreolysis in treating symptomatic vitreous floaters of complete posterior vitreous detachment (PVD) and non-PVD. METHODS: In this prospective cohort study, 51 eyes with symptomatic floaters were treated with YAG laser vitreolysis. Participants were divided into complete PVD and non-PVD groups. Objective visual quality measures including the Strehl ratio (SR), internal spherical aberration (SA), internal comatic aberration (CA), internal high-order aberration (HOA), area ratio of modulation transfer function (MTFa) and Vitreous Floaters Symptom Questionnaire (VFSQ-13) scores were used to compare the efficacy of YAG laser vitreolysis treatment between two groups. RESULTS: The mean age of all patients was 56.80 ± 10.82 years old. In total, 36 of 51 (70.59%; 95% CI 58.10–83.10) patients reported their symptoms as significant or complete improvement after YAG laser vitreolysis treatment. Post-treatment MTFa, internal SA and internal HOA were significantly better compared to baseline (26.19 ± 14.73 vs. 29.19 ± 17.98, p = 0.013; 0.05 ± 0.05 vs. 0.04 ± 0.04, p = 0.031 and 0.23 ± 0.22 vs. 0.16 ± 0.07, p = 0.044; respectively) in all eyes. Twenty-nine of 51 (56.86%) eyes had floaters of non-PVD type. Significant or complete subjective improvements in the PVD group and non-PVD group were 72.73% and 68.97% (p = 0.344), respectively. CONCLUSIONS: Improved subjective and objective visual quality in participants with symptomatic floaters following YAG laser vitreolysis was found in both groups. The efficacy of YAG laser vitreolysis was comparable in floaters of complete PVD and non-PVD types. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-021-00422-6. Springer Healthcare 2021-11-15 2022-02 /pmc/articles/PMC8770727/ /pubmed/34778916 http://dx.doi.org/10.1007/s40123-021-00422-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Lin, Tiezhu
Li, Tongtong
Zhang, Xinmei
Hui, Yannian
Moutari, Salissou
Pazo, Emmanuel Eric
Dai, Guangzheng
Shen, Lijun
The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD
title The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD
title_full The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD
title_fullStr The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD
title_full_unstemmed The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD
title_short The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD
title_sort efficacy and safety of yag laser vitreolysis for symptomatic vitreous floaters of complete pvd or non-pvd
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770727/
https://www.ncbi.nlm.nih.gov/pubmed/34778916
http://dx.doi.org/10.1007/s40123-021-00422-6
work_keys_str_mv AT lintiezhu theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT litongtong theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT zhangxinmei theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT huiyannian theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT moutarisalissou theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT pazoemmanueleric theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT daiguangzheng theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT shenlijun theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT lintiezhu efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT litongtong efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT zhangxinmei efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT huiyannian efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT moutarisalissou efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT pazoemmanueleric efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT daiguangzheng efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd
AT shenlijun efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd